DTIL
PRECISION BIOSCIENCES INCBS score 33.6LOWPHASE2 · mkt cap $170.6M · rev ttm $34.3M
drug hypothesis
PBGENE-DMD modulates DMD gene (dystrophin restoration) to treat Duchenne Muscular Dystrophy (DMD) with mutations amenable to PBGENE-DMD.
moa:Gene therapy approach designed to deliver functional dystrophin gene to muscle cells in patients with Duchenne Muscular Dystrophy harboring specific mutations amenable to the treatment
score breakdown
trial design70
base rate disconnect4
language red flags20
composite33.6
valuation analysis
market cap$170.6M
revenue ttm$34.3M
phasePHASE2
historical base rate25%
disconnect ratio0.1x
lead trialNCT07429240
meta
cik0001357874
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1/2a, non-randomized, single-arm, open-label study with 18 patients. Not placebo-controlled. Primary completion expected November 2029.
primary endpoint:Incidence, severity, and causality of treatment-emergent adverse events and serious adverse events (From Dosing through Week 104)
claimed differentiation
INSUFFICIENT_DATA - No SEC filing text provided to extract company claims
language red flags
- INSUFFICIENT_DATA - No SEC filing text provided to analyze language
company-stated risks
- INSUFFICIENT_DATA - No risk disclosures provided in available data
upcoming catalysts
- 2026-03Trial initiation
- 2029-11Primary completion / Week 104 safety data